- Investigator-led Phase IIa study met its primary endpoint of disease control rate at 12 weeks -
BERGEN, Norway, June 5, 2023 - BerGenBio ASA , a clinical-stage biopharmaceutical company. | June 5, 2023
Bergen - Reference is made to the stock exchange announcement published by BerGenBio ASA on 25 April 2023, regarding a proposed partially underwritten rights issue of shares with preferential. | May 22, 2023
BERGENBIO ASA - Terms of the partially underwritten rights issue NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED. | May 20, 2023
Q&A regarding the proposed partially underwritten rights issue in BerGenBio ASA As previously announced BerGenBio is seeking funding to further advance the. | May 9, 2023
BERGEN, Norway, Feb. 16, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical